HRP20151382T1 - Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar - Google Patents

Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar Download PDF

Info

Publication number
HRP20151382T1
HRP20151382T1 HRP20151382TT HRP20151382T HRP20151382T1 HR P20151382 T1 HRP20151382 T1 HR P20151382T1 HR P20151382T T HRP20151382T T HR P20151382TT HR P20151382 T HRP20151382 T HR P20151382T HR P20151382 T1 HRP20151382 T1 HR P20151382T1
Authority
HR
Croatia
Prior art keywords
weight
total weight
amount
pharmaceutical preparation
preparation
Prior art date
Application number
HRP20151382TT
Other languages
English (en)
Croatian (hr)
Inventor
Durga Maheswari Parvataneni
Siddhartha YEDLURI
Venkata Satyanarayana APPADWEDULA
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43923331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151382(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Publication of HRP20151382T1 publication Critical patent/HRP20151382T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HRP20151382TT 2011-03-07 2011-08-10 Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar HRP20151382T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1103860.1A GB2488788B (en) 2011-03-07 2011-03-07 Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
EP11764851.9A EP2683381B1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent
PCT/IB2011/001842 WO2012120328A1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent

Publications (1)

Publication Number Publication Date
HRP20151382T1 true HRP20151382T1 (hr) 2016-02-12

Family

ID=43923331

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151382TT HRP20151382T1 (hr) 2011-03-07 2011-08-10 Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar

Country Status (33)

Country Link
US (1) US9895367B2 (enExample)
EP (1) EP2683381B1 (enExample)
JP (1) JP5788534B2 (enExample)
KR (1) KR101767296B1 (enExample)
CN (1) CN103561742B (enExample)
AP (1) AP4076A (enExample)
AU (1) AU2011361921B2 (enExample)
BR (1) BR112013022930A2 (enExample)
CA (1) CA2829015C (enExample)
CO (1) CO6811851A2 (enExample)
CY (1) CY1116968T1 (enExample)
DK (1) DK2683381T3 (enExample)
EA (1) EA024610B1 (enExample)
ES (1) ES2554927T3 (enExample)
GB (1) GB2488788B (enExample)
GE (1) GEP20156410B (enExample)
HR (1) HRP20151382T1 (enExample)
HU (1) HUE025562T2 (enExample)
IL (1) IL228218A (enExample)
MA (1) MA35088B1 (enExample)
MX (1) MX339130B (enExample)
MY (1) MY158693A (enExample)
NZ (1) NZ614903A (enExample)
PH (1) PH12013501844A1 (enExample)
PL (1) PL2683381T3 (enExample)
PT (1) PT2683381E (enExample)
RS (1) RS54420B1 (enExample)
SG (1) SG193349A1 (enExample)
SI (1) SI2683381T1 (enExample)
SM (1) SMT201500235B (enExample)
UA (1) UA111074C2 (enExample)
WO (1) WO2012120328A1 (enExample)
ZA (1) ZA201306643B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374725B (es) * 2015-12-18 2025-03-06 Natco Pharma Ltd Composiciones farmacéuticas que comprenden derivado de fenilaminopirimidina.
EP3397242B1 (en) * 2015-12-29 2021-02-03 Noivita S.R.L.S. Lipophilic formulations
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
CN107564610A (zh) * 2017-10-20 2018-01-09 浙江中大元通特种电缆有限公司 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆
NZ767340A (en) 2018-03-14 2025-11-28 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
AU728698B2 (en) * 1997-07-29 2001-01-18 Boehringer Ingelheim International Gmbh Self-emulsifying formulation for lipophilic compounds
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
EP1498143A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
SI1786799T1 (sl) 2004-09-09 2012-12-31 Natco Pharma Limited Novi derivati fenilaminopirimidina kot inhibitorji BCR-ABL kinaze
KR20090061055A (ko) * 2006-10-26 2009-06-15 시코르, 인크. 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
DE602008003183D1 (de) * 2007-04-30 2010-12-09 Intezyne Technologies Inc Hybride blockcopolymer-mizellen mit gemischter stereochemie zur verkapselung hydrophober stoffe
WO2009109867A2 (en) * 2008-03-04 2009-09-11 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
US8772495B2 (en) * 2008-05-23 2014-07-08 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor

Also Published As

Publication number Publication date
PL2683381T3 (pl) 2016-06-30
US20130338180A1 (en) 2013-12-19
PH12013501844A1 (en) 2015-10-23
CA2829015A1 (en) 2012-09-13
EP2683381A1 (en) 2014-01-15
US9895367B2 (en) 2018-02-20
MX339130B (es) 2016-05-13
EA201391280A1 (ru) 2014-02-28
HUE025562T2 (en) 2016-03-29
MA35088B1 (fr) 2014-05-02
MY158693A (en) 2016-11-15
CY1116968T1 (el) 2017-04-05
ZA201306643B (en) 2014-11-26
CN103561742A (zh) 2014-02-05
DK2683381T3 (en) 2015-12-21
SI2683381T1 (sl) 2016-01-29
JP2014507463A (ja) 2014-03-27
WO2012120328A1 (en) 2012-09-13
MX2013010160A (es) 2013-12-06
IL228218A (en) 2016-06-30
AP2013007128A0 (en) 2013-09-30
AU2011361921A1 (en) 2013-09-26
AP4076A (en) 2017-03-23
RS54420B1 (sr) 2016-04-28
NZ614903A (en) 2014-08-29
GB201103860D0 (en) 2011-04-20
AU2011361921B2 (en) 2016-06-09
KR101767296B1 (ko) 2017-08-10
ES2554927T3 (es) 2015-12-28
CA2829015C (en) 2018-01-02
PT2683381E (pt) 2015-11-02
CN103561742B (zh) 2016-04-27
CO6811851A2 (es) 2013-12-16
BR112013022930A2 (pt) 2016-12-06
JP5788534B2 (ja) 2015-09-30
EA024610B1 (ru) 2016-10-31
GEP20156410B (en) 2015-12-10
SMT201500235B (it) 2015-10-30
UA111074C2 (uk) 2016-03-25
AU2011361921A2 (en) 2014-10-30
SG193349A1 (en) 2013-10-30
GB2488788B (en) 2013-07-10
KR20140016926A (ko) 2014-02-10
GB2488788A (en) 2012-09-12
EP2683381B1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
HRP20151382T1 (hr) Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar
KR102180667B1 (ko) 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법
BRPI0710611A2 (pt) composições farmacêuticas e seus usos
JP2023153863A (ja) １５－ｈｅｐｅを含む組成物及びその使用方法
JP5286086B2 (ja) 還元型補酵素ｑ１０及びリゾレシチンを含有する組成物
JP2014504259A5 (enExample)
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения
RU2015131700A (ru) Фармацевтические композиции, включающие производное камптотецина
ES2242061T3 (es) Composicion que comprende paracetamol y un componente de enmascaramiento del amargor.
JP2013515018A5 (enExample)
CN111491625B (zh) 溶解尿酸单钠以治疗痛风
JP2016512828A5 (enExample)
RU2015144013A (ru) Липидные композиции рацекадотрила
JP2015516418A5 (enExample)
JP2025061087A (ja) １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法
CA3098112A1 (en) Pharmaceutical formulation
CN110494415A (zh) 具有改善的稳定性的制剂
JP2023518822A (ja) ｐＨ依存的再構築が可能な医薬キャリア、その製造方法及び使用方法
RU2020111980A (ru) Фармацевтическая композиция
TW201642844A (zh) 外用醫藥組合物
JP7751969B2 (ja) 外用乳化組成物
JP6900189B2 (ja) 外用組成物
CN111356450A (zh) Pde5抑制剂的液体填充制剂
JP2018104368A (ja) 外用組成物
CN115397470A (zh) 具有改善的自愿接受度的组合物